NCT04309591|Completed
Loading search results
Sponsor study identifier
Secondary identifiers
NIH
observational
249
1 country
1
Study Start
October 18, 2019
Actual (reported)Primary Completion
December 4, 2019
Actual (reported)Study Completion
December 4, 2019
Actual (reported)Cardiopulmonary surgery is associated with inflammatory responses that can lead to systemic inflammatory responses (SIRS), organ dysfunction (MOD) and death especially in patients with endocarditis. Cytokine removal might therefore improve outcomes of patients undergoing cardiac surgery. CytoSorb is a device designed to remove cytokine (IL-6, IL-10, TNFalpha) from the blood to reduce immune reactions. This trial investigates the use of CytoSorb during cardiac surgery in patients with endocarditis at the University Hospital Basel.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 4, 2019
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 18, 2019
Actual (reported)December 4, 2019
Actual (reported)December 4, 2019
Actual (reported)March 12, 2020
Actual (reported)March 16, 2020
Actual (reported)In-Hospital mortality
In-Hospital mortality (number of deaths) of patients with endocarditis undergoing cardiac surgery and intra-operative CytoSorb haemoadsorption
during hospital stay for cardiac surgery from admission until discharge (approximately 15 days)
time in intensive care unit (days)
during hospital stay for cardiac surgery from admission until discharge (approximately 15 days)
In-Hospital time (days)
hospital stay for cardiac surgery from admission until discharge (approximately 15 days)
CytoSorb® cartridges contain biocompatible sorbent polystyrene divinylbenzene beads coated with polyvinylpyrrolidone, capable of removing inflammatory molecules (eg Interleukin). The cartridge is inserted in a cardio-pulmonary bypass circuit to remove inflammatory molecules during cardiac surgery .
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
patients with endocarditis undergoing cardiac surgery with cardio-pulmonary bypass circuit at the University Hospital Basel
Klinik für Herzchirurgie, Universitätsspital Basel
Basel, 4031, Switzerland
David Santer, Dr. med
Universitätsspital Basel, Herzchirurgie
249 participants (actual enrollment reported by the registry).
First Submitted
March 12, 2020
First Posted
March 16, 2020
Study Start
October 18, 2019
Actual (reported)Contact the study team to confirm eligibility.
Primary Completion
December 4, 2019
Actual (reported)Study Completion
December 4, 2019
Actual (reported)Last Updated
March 16, 2020
Record last verified: 2020-03
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: